A dose blocked‐randomized, double‐blind, placebo‐controlled, single ascending dose study anlysing safety of Hsg4112 in healthy volunteers
Latest Information Update: 23 Apr 2021
At a glance
- Drugs Vutiglabridin (Primary)
- Indications Obesity
- Focus Adverse reactions; First in man; Pharmacokinetics
- 23 Apr 2021 New trial record
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics